BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

NCT04563195 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Drug unavailable

Conditions

Interventions

Sponsor

Matthew C. Baker